期刊
ANNUAL REVIEW OF MEDICINE
卷 56, 期 -, 页码 29-44出版社
ANNUAL REVIEWS
DOI: 10.1146/annurev.med.56.082103.104727
关键词
lymphoma; Epstein-Bair virus; solid organ transplant; hematopoietic stem cell transplant; immunotherapy
资金
- NCI NIH HHS [P01 CA094237, R01 CA94237, CA61384] Funding Source: Medline
- NCRR NIH HHS [RR00188] Funding Source: Medline
- NATIONAL CANCER INSTITUTE [R01CA061384, U01CA061384, P01CA094237] Funding Source: NIH RePORTER
Post-transplant lymphoproliferative disorder (PTLD) is a life-threatening complication after hematopoietic stem cell or solid organ transplantation. The majority of PTLD is of B-cell origin and associated with Epstein-Barr virus (EBV). During the past decade progress has been made in better understanding the pathogenesis of PTLD, and early detection strategies, such as serial measurement of EBV-DNA load in peripheral blood samples, have assisted in the identification of high-risk patients. In addition, novel immunotherapies have been developed, including the use of monoclonal antibodies and adoptive transfer of EBV-specific T cells. Despite these advances, it remains a major challenge to define indications for preemptive therapies for PTLD and to integrate novel therapeutic approaches with conventional therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据